Patent Law Implications In Indonesia’S Agricultural Biotechnology Innovations

01 Apr 2026 --
0 Comments

📌 1. Indonesia’s Patent Framework & Biotechnology

Patent Law Basics in Indonesia

Indonesia’s current patent regime is governed by Undang‑Undang No. 13 Tahun 2016 tentang Paten (Patent Law) and its implementing regulations. Patents are exclusive rights granted for inventions in all fields of technology that are new, inventive, and industrially applicable.
A key limitation: patent rights cannot be granted to all living things, essential biological processes for producing plants/animals, and certain categories of subject matter (e.g., plants per se, animal varieties) as stipulated in the law. The Patent Law excludes, for example, “all living things, except micro‑organisms” and certain biological processes.
Concurrently, Plant Variety Protection (PVP) is governed by a separate statute, Law No. 29 of 2000, which specifically protects new plant varieties but not biotechnological processes.

From this framework arise multiple legal implications: when is a biotechnological product patentable vs excluded, how are biotech patents litigated, and what degree of patent protection is granted in disputes.

🔎 2. Case Law & Jurisprudential Developments in Indonesia

Unlike some jurisdictions (e.g., USA) with well‑documented judicial decisions on biotech patents, formal published Indonesian case law on agricultural biotechnology patent disputes is limited in open sources. However, several reported decisions, jurisprudential rulings, and administrative decisions illustrate how patent law operates in practice.

✅ Case 1: Patent Process Infringement – Herbisida Process Dispute

This decision comes from Indonesian jurisprudence and illustrates how courts evaluate process patents.

Issue: A patent owner sued another party for using a patented process to produce a herbicide without permission. The patent covered a specific technical process.
Court Holding: The court (Judex Factie) dismissed the plaintiff’s case because the plaintiff failed to detail exactly which part of its patented process was allegedly infringed — whether formulation, procedural steps, or use. Without this clarity, the infringement claim lacked specificity.
Legal Implication: In process patent cases, Indonesian courts require clear linkage between the defendant’s acts and the exact claimed steps in the patent. A broad allegation is insufficient to support infringement. This decision demonstrates that mere similarity in outcome (e.g., producing a herbicide) is not enough; the specific process details matter.

✅ Case 2: Patent Appeal & Correction — Biotech‑Related Patent Appeal

This example arises from decisions by the Patent Appeal Commission (Komisi Banding Paten).

Dispute: A multinational company (Arcellx, Inc.) sought correction to the description and claims of its Indonesian patent (Patent No. IDP000096741) relating to a biotechnological invention (immune cell therapy).
Outcome: The Appeal Commission accepted the requested correction, finding compliance with statutory requirements for correction under Articles 39 and 69 of the Patent Law (allowing limited corrections post‑grant when justified).
Significance: This case reflects that patent appeal mechanisms in Indonesia allow patentees to refine biotech patent claims and descriptions — a key procedural tool, especially where biotech inventions evolve. It also signals that administrative review can reinforce legal certainty.

✅ Case 3: Patent Grant & Public Interest — Civil Society Challenge

Although not a traditional “patent infringement case,” this ongoing constitutional review challenge reflects dramatic implications for biotechnology, including agricultural biotech.

Context: Civil society groups have filed a challenge at the Indonesian Constitutional Court against the amended Patent Law (Law No. 65 of 2024), arguing it weakens safeguards against evergreening (granting patents on trivial modifications) — a concern especially in pharma and biotech.
Concern: Removal of certain provisions (e.g., Article 4(f) of the old law) may allow patents for incremental uses of known compounds or processes that do not represent substantive innovation.
Implication for Agricultural Biotech: Although the complaint focuses on medicine patents, the same legal principle applies: stronger patentability standards prevent unauthorized monopoly extensions on biological processes or products that might be obvious or already known. These standards influence how agricultural biotech innovators are evaluated legally.

✅ Case 4: Non‑Patentable Subject Matter — Exclusion of Biological Processes

While not a single case, Indonesian jurisprudence has consistently upheld that essentially biological processes for producing plants/animals are non‑patentable.

Application: Developed through administrative examination and often upheld on appeal, Indonesia’s Patent Law excludes these processes — meaning a genetic breeding technique used mainly as a natural replication step cannot be patented.
Implication: Agriculture innovators must structure inventions around non‑biological or microbiological interventions (e.g., genetic modification techniques, engineered materials) to secure patent protection. This affects R&D strategies.

✅ Case 5: International Comparators & Influence (U.S. Biotech Patent Decisions)

Although not Indonesian cases per se, major U.S. decisions like Bowman v. Monsanto and J.E.M. Ag Supply v. Pioneer shape thinking on agricultural biotech patent policy globally.

In Bowman v. Monsanto, the U.S. Supreme Court held that a farmer replanting patented genetically modified seeds without a license infringes patent rights — signaling strong enforcement for biotech seeds.
In J.E.M. Ag Supply v. Pioneer, the court affirmed that sexually reproduced plants are patentable subject matter, clarifying that plant varieties can be protected under utility patents beyond plant variety protection.

While Indonesian courts do not formally bind themselves to these foreign decisions, these cases are persuasive in academic and policy discussions — especially in determining how subject matter eligibility and infringement logic should be interpreted in complex biotech cases.

⚖️ 3. Broad Legal Implications for Agricultural Biotech Innovators

🧬 A. Scope of Patentability

Plant varieties per se are excluded, pushing innovators to rely on process patents, genetic constructs (microbiological), and engineered traits — provided they meet novelty, inventive step, industrial application.
Innovators must carefully draft applications to focus on technical methods or non‑biological/microbiological components to clear statutory exclusions.

📋 B. Enforcement and Litigation

Courts require precise claim comparisons in infringement disputes. Ambiguous allegations often fail.
Administrative review (Patent Appeal Commission) can correct granted patents, affecting enforcement and legal certainty.
No full body of published Supreme Court decisions yet exists in Indonesia on agricultural biotech; many disputes are resolved administratively or through negotiated settlements.

⚖️ C. Public Interest & Constitutional Review

Advocacy and constitutional challenges underscore tensions between innovation incentives and public access/anti‑monopoly concerns, relevant for biotech products with wide societal impact.

📝 4. Practical Takeaways for Innovators

✅ Patent Strategizing

Draft biotech patents narrowly but technically — emphasize engineered methods, molecular steps, or bioinformatics algorithms rather than natural processes.
Consider Plant Variety Protection in addition to patents where applicable (e.g., new crop varieties).

✅ Avoid Patent Pitfalls

Ensure detailed claim language — vague claim scope opens vulnerability in enforcement.
Pay attention to statutory exclusions (biological process carve‑outs).

✅ Monitor Legal Reform

Recent amendments and constitutional challenges could reshape how biotech patents are assessed.

📊 Conclusion

Indonesia’s patent law does protect agricultural biotechnology inventions, but with clear boundaries. Inventors must navigate statutory exclusions, rigorous claim requirements, and enforceability challenges. Cases — though not yet numerous in Indonesia’s published jurisprudence — highlight that both administrative bodies and courts insist on technical clarity, precise claim comparison, and adherence to patent eligibility criteria before granting or enforcing rights.

This interplay shapes real‑world innovation — promoting some biotechnological progress while tempering overly broad or ethically questionable claims. The dynamic nature of reforms and public interest litigation further underscores that agricultural biotech patents remain at the forefront of Indonesian IP law evolution.